Drug intelligence / Profile preview

J021-0199

Development stage: Preclinical
Lead developer: University of Florida

Overview

J021-0199: sourced facts only. name: "Biochemical assays demonstrated that J021-0199 binds to the N-terminal TIM barrel domain of PRMT5." [PMID:40365403]; target: "Biochemical assays demonstrated that J021-0199 binds to the N-terminal TIM barrel domain of PRMT5." [PMID:40365403]; developer: "Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida 32610, United States." [PMID:40365403]; stage: "In CRPC cell lines (LNCaP and 22Rv1), J021-0199 selectively inhibited cancer cell growth." [PMID:40365403]

Targets

PRMT5 (Protein arginine N-methyltransferase 5)

Beyond the preview

Go deeper on J021-0199.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on J021-0199.